Cocrystal Pharma (COCP) Fundamental Analysis: Revenue, Earnings & Valuation

6.25 / 10

Netural

The company exhibits positive fundamental metrics (6.2/10). Strengths observed in Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, while concerns exist in Asset-MV and Fixed assets turnover ratio. Lead to favorable appraisal.

Analysis Checks(8/10)

Revenue-MV

Value-0.18

Score3/3

Weight35.91%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value142.08

Score2/3

Weight1.45%

1M Return0.41%

Inventory turnover ratio

Value98.02

Score2/3

Weight-3.76%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight15.67%

1M Return4.10%

PB-ROE

Value-0.03

Score3/3

Weight46.46%

1M Return10.40%

Fixed assets turnover ratio

Value8528.00

Score1/3

Weight-5.45%

1M Return-1.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-3.49%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value185.72

Score2/3

Weight2.41%

1M Return0.68%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-4.38%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight15.19%

1M Return3.90%

Is COCP fundamentally strong?

COCP scores 6.25/10 on fundamentals and holds a Fair valuation at present. Backed by its -111.40% ROE, 0.00% net margin, -2.36 P/E ratio, 3.29 P/B ratio, and 54.65% earnings growth, these metrics solidify its Netural investment rating.